Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial

References

• Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 1999; 52: 1427–33
   PubMed Web of Science ®Google Scholar
• Groeneveld G. J., Veldink J. H., van der Tweel I., Kalmijn S., Beijer C., de Visser M., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45
   PubMed Web of Science ®Google Scholar
• Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996; 46: 1244–9
   PubMedGoogle Scholar
• Miller R. G., Moore D., Young L. A., Armon C., Barohn R. J., Bromberg M. B., et al. Placebo‐controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996; 47: 1383–8
   PubMed Web of Science ®Google Scholar
• Miller R. G., Moore DH I. I., Gelinas D. F., Dronsky V., Mendoza M., Barohn R. J., et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–8
   PubMed Web of Science ®Google Scholar
• Cudkowicz M. E., Shefner J. M., Schoenfeld D. A., Brown RH Jr., Johnson H., Qureshi M., et al. A randomized, placebo‐controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003; 61: 456–64
   PubMed Web of Science ®Google Scholar
• Lai E. C., Felice K. J., Festoff B. W., Gawel M. J., Gelinas D. F., Kratz R., et al. Effect of recombinant human insulin‐like growth factor‐I on progression of ALS. A placebo‐controlled study. The North America ALS/IGF‐I Study Group. Neurology 1997; 49: 1621–30
   PubMed Web of Science ®Google Scholar
• Borasio G. D., Robberecht W., Leigh P. N., Emile J., Guiloff R. J., Jerusalem F., et al. A placebo‐controlled trial of insulin‐like growth factor‐1 in amyotrophic lateral sclerosis. European ALS/IGF‐I Study Group. Neurology 1998; 51: 583–6
   PubMed Web of Science ®Google Scholar
• Shefner J. M., Cudkowicz M. E., Schoenfeld D., Conrad T., Taft J., Chilton M., et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• Gordon P. H., Miller R. G., Moore D. H. ALSFRS‐R. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))90–3
   PubMed Web of Science ®Google Scholar
• Scelsa S. N., MacGowan D. J., Mitsumoto H., Imperato T., LeValley A. J., Liu M. H., et al. A pilot, double‐blind, placebo‐controlled trial of indinavir in patients with ALS. Neurology 2005; 64: 1298–300
   PubMed Web of Science ®Google Scholar
• Mitsumoto H., personal communication, The TCH346 (Novartis) Study
   Google Scholar
• Gordon P. H., personal communication, Ongoing Phase III Trial of minocycline for the treatment of ALS
   Google Scholar
• Moore D. H., Miller R. G., WALS Study Group, ALS CARE Study Group. ALSFRS as a measure of disease progression and survival. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4: 42, C50
   Google Scholar
• Cedarbaum J. M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Traynor B. J., Zhang H., Shefner J. M., Schoenfeld D., Cudkowicz C. E. Functional outcome measures as a clinical trial endpoint in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 42, C51
   Google Scholar
• Kaufmann P., Levy G., Thompson J. L., Delbene M. L., Battista V., Gordon P. H., et al. The ALSFRS‐R predicts survival time in an ALS clinic population. Neurology 2005; 64: 38–43
   PubMed Web of Science ®Google Scholar
• Cedarbaum J. M., Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997; 152((Suppl 1))S1–9
   PubMed Web of Science ®Google Scholar
• Miano B., Stoddard G. J., Davis S., Bromberg M. B. Inter‐evaluator reliability of the ALS Functional Rating Scale. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 235–9
   PubMed Web of Science ®Google Scholar
• Brooks B. R. Functional Scales: Summary. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: S13–8
   PubMed Web of Science ®Google Scholar
• Kasarskis E. J., Dempsey‐Hall L., Thompson M. M., Luu L. C., Mendiondo M., Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS‐R. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 50–4
   PubMed Web of Science ®Google Scholar
• Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., et al. A two‐stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology, 2006, in press
   Google Scholar
• Shrout P., Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 1979; 86: 420–8
   PubMed Web of Science ®Google Scholar
• Fleiss J. L. The design and analysis of clinical experiments. 2nd edition. N. J Hoboken, 1986, John Wiley and Sons
   Google Scholar
• Thompson J. L., Levy G. ALS issues in clinical trials. Missing data. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl) 1)48–51
   Google Scholar